API/FDF Technology Transfer
API/FDF Technology Transfer
Technology Craft Limited (TCL) specializes in facilitating the transfer of global mature Finished Dosage Form (FDF) technology, addressing the growing demands of Chinese pharmaceutical companies eager to accelerate product development and market entry. With a focus on the pharmaceutical market in China, we connect pharmaceutical firms with international technology providers, enabling efficient FDF technology transfer, registration, and commercialization.
Our Expertise: TCL has over 20 years of industry experience and maintains long-term cooperation with more than 2,000 well-known pharmaceutical companies and research institutes in China. We understand the intricacies of the Chinese market and offer tailored solutions for pharmaceutical companies looking to bring innovative products to market quickly and efficiently.
Our services include:
Technology Transfer: We bridge the gap between international FDF technology providers and Chinese pharmaceutical firms.
Regulatory Compliance & Registration: Ensuring all products meet local Chinese pharmaceutical regulations and standards.
Commercialization Support: Helping businesses navigate the process of launching products and expanding into the Chinese market.
Docked Finished Dosage Forms (FDF): Technology Craft Limited has facilitated the docking and introduction of a wide variety of Finished Dosage Forms (FDFs), tailored to meet the specific needs of Chinese pharmaceutical companies. If you have strong, innovative FDF technologies, we invite you to contact us for potential partnerships.
Name | Dosage Form Strength | Regulatory Status | Developable Market | Project Type |
Mirabegron | Sustained release tablet:25mg、50mg | Approved by EU | All markets | Tech-transfer |
Succinylcholine | Injection:20mg/ml | Under review in US-FDA | All markets | Tech-transfer |
Glycopyrrolate | Injection:0.2mg/ml | Under review in US-FDA | All markets | Tech-transfer |
Eribulin | Injection:1mg/2ml (0.5mg/ml) | Available for European and American markets | All markets | Tech-transfer |
Osimertinib | Tablet:40mg、80mg | Available for European and American markets | All markets | Tech-transfer |
Bivalirudin | Injection:250mg/vial Solution:250mg/50ml (5mg/ml) 、500mg/100ml (5mg/ml) |
Available for European and American markets | All markets | Tech-transfer |
Doxylamine succinate+Pyridoxine HCl | Sustained release tablet:10 mg | Filing in FDA | All markets | Tech-transfer |
Tenofovir Alafenamide Fumarate | Tablet:25 mg | Filing in FDA | All markets | Tech-transfer |
Tolvaptan | Tablet:15 & 30 mg | Filing in FDA | All markets | Tech-transfer |
Dolutegravir | Tablet: 50 & 300 mg | Filing in FDA | All markets | Tech-transfer |
Pentoxifylline | Sustained release tablet:400mg | Approved by EU Approved by US-FDA |
All markets | Tech-transfer |
Esomeprazole Magnesium | Sustained release tablet:375mg;500mg Extended release capsules:20mg; 40mg |
Approved by US-FDA | All markets | Tech-transfer & API |
Voriconazole | Suspension:200mg/5ml Injection:200mg/vial Tablet:20mg;50mg |
Filing in FDA | All markets | Tech-transfer & API |
Dabigatran Etexilate Mesylate | Capsule:75mg,110mg,150mg | Filing in FDA | All markets | Tech-transfer & API |
Sevelamer | Tablet:800mg Suspending Agent:2.4mg/packet、800mg/packet |
Available for European and American markets | All markets | Tech-transfer & API |
Mirabegron | Sustained release tablet:25mg、50mg | Approved by EU | All markets | License-in |
Abacavir Sulfate | Injection:20mg/ml, Tablet:300mg |
Approved by US-FDA | All markets | License-in |
Ritonavir | Tablet:100mg | Approved by US-FDA | All markets | License-in |
Roflumilast | Tablet:500mg | Approved by US-FDA | All markets | License-in |
Etomidate Injectable Emulsion | Injection:2mg/ml | Approved by EU Approved by US-FDA |
All markets | License-in |
Atazanavir Sulfate | Capsule:150mg | Approved by US-FDA | All markets | License-in |
Colesevelam Hydrochloride Tablets | Tablet:625mg | Approved by US-FDA | All markets | License-in |
Lurasidone Hydrochloride Tablets | Tablet:20mg、40mg、60mg、80mg | Approved by US-FDA | All markets | License-in |
Teriflunomide Tablets | Tablet:7 mg 、14 mg | Approved by US-FDA | All markets | License-in |
Pramipexole | Tablet:0.125mg、0.25mg、0.5mg、0.75mg、1mg、1.5mg | Approved by US-FDA | All markets | License-in |
Efavirenz | Tablet:600mg | Approved by EU Approved by US-FDA |
All markets | License-in |
Fosaprepitant | Injection:115mg/10ml | Easy to register in China; Approved by US-FDA |
All markets | License-in |
Dofetilide | Tablet/Capsule:125mcg,250mcg,500mcg | Approved by US-FDA | All markets | License-in |
Brivaracetam | Tablet:10 mg,25 mg,50 mg,75 mg,100 mg | Easy to register in China; Approved by US-FDA |
All markets | License-in |
Thiotepa | Injection:10mg/ml | Clinical research have done on the basis of original drugs; Approved by US-FDA |
All markets | License-in |
Bosutinib | Tablet:100 mg、400 mg、500 mg | Clinical research have done on the basis of original drugs; Approved by US-FDA |
All markets | License-in |
Linagliptin | Tablet,Sustained release tablet:5mg | Approved by US-FDA | All markets | License-in |
metformin+linagliptin | Tablet,Sustained release tablet:2.5mg: 850mg | Approved by US-FDA | All markets | License-in |
empagliflozin | Tablet:1g,10g,100g,1kg,10kg,100kg | Approved by US-FDA | All markets | License-in |
Levosimendan Injection | Injection:5ml,12.5mg | Approved by EU | All markets | License-in |
OSELTAMIVIR PHOSPHATE | Dry Suspension:6mg/ml | Approved by US-FDA | All markets | License-in |
Iron sucrose injection | Injection:100mg/5ml | Approved by US-FDA | All markets | License-in |
ESCITALOPRAM OXALATE | Oral Solution:5mg/5ml | Approved by EU Approved by US-FDA |
All markets | License-in |
Posaconazole | Injection:200 mg/5 ml | Approved by Eastern Europe | All markets | License-in |
sugammadex sodium | Injection: 500mg/5ml;200mg/2ml | Filing in US-FDA | All markets | License-in |
BILASTINE | Film coated tablet: 20mg | Filing completed in EU and US-FDA in the fourth quarter of 2020 | All markets | License-in |
RASAGILINE MESYLATE | Tablet:0.5mg,1mg | Approved by EU | All markets | License-in |
Chloroquine Diphosphate | Tablet:250mg,500mg | Ready to list on US-FDA | All markets | License-in |
Doxylamine succinate+Pyridoxine HCl | Sustained release tablet:10 mg | Filing in US-FDA | All markets | License-in |
Tenofovir Alafenamide Fumarate | Tablet:25 mg | Filing in US-FDA | All markets | License-in |
Tolvaptan | Tablet:15 and 30 mg | Filing in US-FDA | All markets | License-in |
Dolutegravir;Lamivudine;Tenofovir Disoproxil Fumarate | Tablet:50 and 300 mg | Filing in US-FDA | All markets | License-in |
Pentoxifylline | Sustained release tablet:400mg Injection:100mg/5ml;100mg/2ml |
Approved by EU Approved by US-FDA |
All markets | License-in |
Azelaic Acid | GEL:15% | Approved by US-FDA | All markets | License-in |
Calcipotriene | Cream;0.005% Ointment:0.005% |
Approved by US-FDA | All markets | License-in |
Clotrimazole and Betamethasone Dipropionate | Cream:1% | Approved by US-FDA | All markets | License-in |
Lidocaine | Ointment:5% | Approved by US-FDA | All markets | License-in |
Dabigatran Etexilate Capsules | Capsule:75mg,110mg,150mg | Approved by US-FDA | All markets | License-in |
Ezetimibe simvastatin | Tablet:10mg,20mg,40mg,80mg | Approved by EU Approving in US-FDA |
All markets | License-in |
Cabazitaxel | Injection:60mg/1.5ml (40mg/ml) | Approving in US-FDA | All markets | License-in |
Etonogestrel | Implant: 68mg Vaginal ring:0.12mg/24 Hours |
Approved by EU | All markets | License-in |
Deferasirox | Dispersible tablet: 90 mg, 180 mg, 360 mg | Approving in US-FDA | All markets | License-in |
Ivabradine | Tablet:2.5mg、5mg、7.5 mg | Approved by EU | All markets | License-in |
Ibandronate | Tablet:150 mg | Approved by EU | All markets | License-in |
Dasatinib | Tablet: 20mg、 50mg、 70mg、80mg、100mg、140mg | Approved by EU | All markets | License-in |
Chloroquine Diphosphate | Tablet:250mg | Approved by EU | All markets | License-in |
Eplerenone | Tablet:25mg,50 mg | Approved by EU | All markets | License-in |
Rasagiline | Tablet:1 mg | Approved by EU | All markets | License-in |
Anagrelide | Capsule:0.5mg, 1 mg | Approved by EU | All markets | License-in |
Bendamustine | Injection:25mg/vial, 100 mg/vial | Approved by EU | All markets | License-in |
Erlotinib | Tablet:25mg,100 mg,150mg | Approved by EU | All markets | License-in |
Sevelamer | Tablet:800mg Suspending Agent:2.4mg/packet、800mg/packet |
Available for European and American markets | All markets | License-in |